LMWH hematoma warning need not be extended to other anticoagulants, FDA committee agrees.
Executive Summary
LMWH HEMATOMA WARNING NEED NOT BE EXTENDED TO OTHER ANTICOAGULANTS, FDA's Anesthetic & Life Support Drugs Advisory Committee agreed at a meeting Feb. 5. The committee voted 5-3 against extending a class boxed warning for low molecular weight heparin products concerning the incidence of spinal hematoma to the labeling of other anticoagulant products such as heparin and DuPont Merck's Coumadin (warfarin).